Four Universities Launch $2.5 Million Study to Define What Lewy Body Biomarker Tests Mean for Patients

The Lewy Body Dementia Association has funded a new multi-site study, called Clin-Syn, led by researchers at UT Health San Antonio and the University of Florida, to determine what positive or negative alpha-synuclein biomarker results should mean for diagnosis and care.

The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio has received a $2.5 million award from the Lewy Body Dementia Association to lead a national study aimed at telling clinicians what new alpha-synuclein biomarker tests actually mean for the people who take them, according to a UT Health San Antonio news release published July 21, 2026. The study, called Clin-Syn, is led jointly with the University of Florida and run in collaboration with the University of California, San Francisco and Virginia Commonwealth University.

Alpha-synuclein, the misfolded protein that clumps into Lewy bodies inside brain cells, historically could only be confirmed after death, according to the UT Health San Antonio release. Newer tests can now detect the protein in skin, blood, saliva and spinal fluid samples from living patients, but researchers say it remains unclear what a given result should tell a clinician about a person's diagnosis, prognosis or treatment plan. Breton Asken, of the University of Florida, and Jeremy Tanner, of UT Health San Antonio, who lead the study, said the goal is to help clinicians "communicate results and guide management decisions", per the University of Florida's August 3, 2026 account of the project.

The study plans to enroll 125 people in total: 50 with early symptoms of dementia with Lewy bodies, 50 with early symptoms of Alzheimer's disease, and 25 adults with no cognitive symptoms, according to the UT Health San Antonio release. Each participant will complete a single comprehensive research visit that includes a neurological exam, cognitive testing, brain scans, skin and blood sample collection, a lumbar puncture, saliva collection, and optional stool sample and brain donation enrollment. Matthew Barrett, who leads the Virginia Commonwealth University site, said the collaboration is meant to help "transform how we diagnose and eventually treat those affected by dementia with Lewy bodies", according to VCU Health's July 22, 2026 report on the study.

More than 1 million Americans are estimated to have Lewy body disease, making it the second most common neurodegenerative dementia after Alzheimer's, according to Lewy Body Dementia Association figures cited in the University of Florida account. The study has only just launched and has not yet enrolled its full cohort or produced findings; any conclusions about what specific biomarker results mean for individual patients remain to be established once data collection and analysis are complete.

Enrollment is beginning across the four sites, and researchers say results are still to come; families and clinicians looking for guidance on what a specific biomarker test result means today should continue to rely on their own care team rather than on this study's eventual findings.